%0 Journal Article
%A Leonide, A.
%A Rüger, B.
%A Weber, A.
%A Meulenberg, W. A.
%A Ivers-Tiffée, E.
%T Impedance Study of Alternative (La,Sr)FeO3-and (La,Sr)(Co,Fe)O3- MIEC Cathode Compositions
%J Journal of the Electrochemical Society
%V 157
%@ 0013-4651
%C Pennington, NJ
%I Electrochemical Society
%M PreJuSER-10137
%P B234 - B239
%D 2010
%Z Funding by the Fuel Cell Research Alliance Baden-Wurttemberg (project 23-729.90 5/371) is gratefully acknowledged.
%X This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
%F PUB:(DE-HGF)16
%9 Journal Article
%U <Go to ISI:>//WOS:000273222700026
%R 10.1149/1.3265473
%U https://juser.fz-juelich.de/record/10137